Trial Profile
A Longitudinal Study Evaluating Molecular Changes Associated With Resistance to First and Third (AZD9291) Generation EGFR TKIs in Patients With EGFR Mutant NSCLC Using "Liquid Biopsy"
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- 05 Jan 2023 The trial has been completed in Greece, according to European Clinical Trials Database record.
- 13 Apr 2022 Results (n=48) detecting EGFR mutations in plasma cfDNA and paired CTC-fractions of NSCLC patients before the initiation of osimertinib presented at the 113th Annual Meeting of the American Association for Cancer Research
- 04 Jun 2019 Results assessing efficacy outcomes without the T790M mutation in ctDNA at baseline published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).